{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:17:47Z","timestamp":1780370267992,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Low-dose (0.5 mg\/day) colchicine improves cardiovascular outcomes in patients with stable coronary disease. Around 10\u201315% of these patients simultaneously use anticoagulant therapy, including vitamin-K antagonists (VKAs). In vitro studies and case reports have described a possible interaction between colchicine and VKAs leading to increased INR, but controlled studies are lacking.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The aim of this study was to investigate if there is a drug-drug interaction between low-dose colchicine and VKAs in patients with chronic coronary disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was a sub-analysis of the randomized low-dose colchicine for secondary prevention of cardiovascular disease 2 (LoDoCo2) trial. This placebo-controlled trial investigated efficacy of colchicine 0.5\u00a0mg once daily in patients with chronic coronary disease. For the current study, we included\u00a0a selection of Dutch patients who concomitantly used a VKA. Following a 30\u00a0days open-label colchicine run-in phase, patients were randomized to colchicine or placebo. The primary outcome was the intra-patient difference in international normalized ratio (INR) during the first month after <jats:italic>starting<\/jats:italic> or <jats:italic>stopping<\/jats:italic> colchicine as compared to the preceding month. Secondary outcomes included changes in VKA daily dosage, assessed in the same pattern and before and after randomization, and time in therapeutic range (TTR), assessed before and after randomization to reflect long-term effects. INR measurements were part of routine clinical care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 73 patients were included (35 colchicine and 38 in the placebo group). No significant intra-patient change in INR was observed after <jats:italic>starting<\/jats:italic> colchicine during the open-label run-in phase (mean INR: 2.60 before vs. 2.67 during run-in, difference 0.07, 95% CI\u2009\u2212\u20090.13 to 0.26; <jats:italic>p<\/jats:italic>\u2009=\u20090.50). Similarly, <jats:italic>stopping<\/jats:italic> colchicine treatment (i.e., randomization to placebo) did not significantly alter INR levels (mean INR: 2.70 during run-in vs. 2.81 after randomization, difference 0.11, 95% CI\u2009\u2212\u20090.12 to 0.33; <jats:italic>p<\/jats:italic>\u2009=\u20090.34). The change in mean VKA daily dosage was\u2009\u2212\u20090.01\u00a0mg (95% CI\u2009\u2212\u20090.03 to 0.01; <jats:italic>p<\/jats:italic>\u2009=\u20090.35) when starting colchicine and\u2009\u2212\u20090.01\u00a0mg (95% CI\u2009\u2212\u20090.03 to 0.01; <jats:italic>p<\/jats:italic>\u2009=\u20090.41) when switching to placebo. TTR in patients allocated to active treatment was 65.8% in the year prior to the start of colchicine and 73.4% in the year after randomization to colchicine (change in TTR 7.56%, 95% CI\u2009\u2212\u20090.14 to 15.26%; <jats:italic>p<\/jats:italic>\u2009=\u20090.05). Mean VKA dosage remained similar (change in VKA dosage of 0.01\u00a0mg; 95% CI\u2009\u2212\u20090.11 to 0.13\u00a0mg; <jats:italic>p<\/jats:italic>\u2009=\u20090.84).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>No significant changes in INR, VKA dosage, or TTR in patients using VKAs after starting or stopping colchicine were observed. These results suggest that there is no need for additional INR monitoring beyond the standard of care when using low-dose colchicine, though further studies in larger populations would help to confirm this conclusion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00228-025-03815-9","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:21:57Z","timestamp":1741346517000},"page":"719-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of colchicine on coagulation in patients with chronic coronary disease who use vitamin K antagonists"],"prefix":"10.1007","volume":"81","author":[{"given":"Jeroen P. A.","family":"Houwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Duyvendak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aernoud T. L.","family":"Fiolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"8","key":"3815_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS et al (2022) Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association. Circulation 145(8):e153\u2013e639","journal-title":"Circulation"},{"issue":"25","key":"3815_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM et al (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol 76(25):2982\u20133021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"3815_CR3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119\u20131131","journal-title":"N Engl J Med"},{"issue":"18","key":"3815_CR4","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"1","key":"3815_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"14","key":"3815_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319\u20131330","journal-title":"N Engl J Med"},{"issue":"28","key":"3815_CR7","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","volume":"42","author":"ATL Fiolet","year":"2021","unstructured":"Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC et al (2021) Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J 42(28):2765\u20132775","journal-title":"Eur Heart J"},{"key":"3815_CR8","doi-asserted-by":"crossref","unstructured":"Virani SS, Newby LK, Arnold S V., Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9).","DOI":"10.1161\/CIR.0000000000001183"},{"issue":"1","key":"3815_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/eurjpc\/zwab154","volume":"29","author":"FLJ Visseren","year":"2022","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M et al (2022) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 29(1):5\u2013115","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"3815_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","volume":"81","author":"T Schalekamp","year":"2007","unstructured":"Schalekamp T, Brass\u00e9 BP, Roijers JFM, Van Meegen E, Van Der Meer FJM, Van Wijk EM et al (2007) VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 81(2):185\u2013193","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3815_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2006.04.006","volume":"80","author":"T Schalekamp","year":"2006","unstructured":"Schalekamp T, Brass\u00e9 BP, Roijers JFM, Chahid Y, van Geest-Daalderop JHH, de Vries-Goldschmeding H et al (2006) VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 80(1):13\u201322","journal-title":"Clin Pharmacol Ther"},{"key":"3815_CR12","doi-asserted-by":"crossref","unstructured":"Dvor\u0306\u00e1k Z, Modriansk\u00fd M, Pichard-Garcia L, Balaguer P, Vilarem MJ, Ulrichov\u00e1 J, et al (2003) Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 64(1):160\u20139.","DOI":"10.1124\/mol.64.1.160"},{"issue":"7","key":"3815_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-005-0942-5","volume":"61","author":"V Gras-Champel","year":"2005","unstructured":"Gras-Champel V, Ohlmann P, Polard E, Wiesel ML, Imbs JL, Andr\u00e9jak M (2005) Can colchicine potentiate the anticoagulant effect of fluindione? Eur J Clin Pharmacol 61(7):555\u2013556","journal-title":"Eur J Clin Pharmacol"},{"issue":"218","key":"3815_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ahj.2019.09.011","volume":"1","author":"SM Nidorf","year":"2019","unstructured":"Nidorf SM, Fiolet ATL, Eikelboom JW, Schut A, Opstal TSJ, Bax WA et al (2019) The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. Am Heart J 1(218):46\u201356","journal-title":"Am Heart J"},{"issue":"3","key":"3815_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69(3):236\u2013239","journal-title":"Thromb Haemost"},{"key":"3815_CR16","unstructured":"GIP Databank [Internet]. [cited 2024 Aug 27]. Available from: https:\/\/www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=gebr&item=B01AA"},{"issue":"9","key":"3815_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.4244\/EIJV8I9A163","volume":"8","author":"T Pilgrim","year":"2013","unstructured":"Pilgrim T, Kalesan B, Zanchin T, Pulver C, Jung S, Mattle H et al (2013Jan) Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents. EuroIntervention 8(9):1061\u20131071","journal-title":"EuroIntervention"},{"issue":"3","key":"3815_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0887-2333(02)00004-8","volume":"16","author":"Z Dvorak","year":"2002","unstructured":"Dvorak Z, Ulrichova J, Pichard-Garcia L, Modriansky M, Maurel P (2002) Comparative effect of colchicine and colchiceine on cytotoxicity and CYP gene expression in primary human hepatocytes. Toxicol In Vitro 16(3):219\u2013227","journal-title":"Toxicol In Vitro"},{"issue":"4","key":"3815_CR19","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW (2010) High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060\u20131068","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3815_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","volume":"135","author":"PC Robinson","year":"2022","unstructured":"Robinson PC, Terkeltaub R, Pillinger MH, Shah B, Karalis V, Karatza E et al (2022) Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med 135(1):32\u201338","journal-title":"Am J Med"},{"issue":"3","key":"3815_CR21","doi-asserted-by":"publisher","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","volume":"126","author":"J Ansell","year":"2004","unstructured":"Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists. Chest 126(3):204S-233S","journal-title":"Chest"},{"issue":"12","key":"3815_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","volume":"44","author":"M Ufer","year":"2005","unstructured":"Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet 44(12):1227\u20131246","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03815-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03815-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:21:24Z","timestamp":1744791684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03815-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3815"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03815-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved a re-analysis of data, with additional data obtained from the Dutch Thrombosis Services. The re-analysis fell under previous medical ethics approval and was conducted in compliance with existing approvals ACTRN12614000093684.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}